AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...

UK King’s Daughters became the first hospital in Kentucky — and the only hospital in the region — to offer a new minimally invasive procedure for ...

Normothermic machine perfusion (NMP) to preserve livers prior to transplant was associated with significantly improved ...

AngioDynamics, Inc. announced the commencement of the AMBITION BTK multicenter randomized controlled trial (RCT), which will ...

AngioDynamics (ANGO) announced the start of a randomized study of the Auryon Atherectomy System used in combination with Standard Balloon ...

Innovative muscle patches derived from stem cells demonstrate efficacy in heart repair, improving function in primates and a ...

A maladaptive stress response might be amenable to behavioral or other interventions to lower future CV risk, say researchers ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Q4 2024 Earnings Call Transcript January 28, 2025 Stryker Corporation beats earnings expectations. Reported EPS is $4.01, ...

Acute limb ischemia (ALI) results from a sudden obstruction in the arterial flow to the extremity due to an embolism or thrombosis. Embolic problems result in a greater degree of ischemia than ...

Dihydromyricetin (Dih), a naturally occurring flavonoid, has been identified to exert a protective effect against ischemia/reperfusion injury. However, the detailed mechanisms remain unclear. Here we ...